As mentioned in the introduction, LRRK2 was first recognized as a therapeutic target for treating at least some forms of familial PD as early as 2005 (6, 7), and as a potential target to treat many, if not all, forms of PD in 2018 (8). This evidence concerns the gene LRRK2 and Parkinson disease.